Savient secures US approval of Krystexxa for gout
This article was originally published in Scrip
Savient Pharmaceuticals has secured US FDA approval for its lead drug candidate Krystexxa (pegloticase) to treat gout in adults who do not respond to or who cannot tolerate conventional therapy. However, uncertainty still remains about the price of the drug, the timing of its launch and the size of its potential market.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.